Want to see FHTX full AI Analyst Report?
Top Page
Foghorn Therapeutics
(NASDAQ:FHTX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.00
▼(-5.48% Downside)
Action:Reiterated
Date:07/08/26
The score is held down primarily by weak financial performance (persistent losses, cash burn, and negative equity), which increases reliance on future financing. Technicals are currently strong with price above major moving averages and positive MACD, but momentum is extended (high RSI/Stoch). Valuation is constrained by negative earnings and no dividend support, while recent corporate updates are modestly positive but not yet fully de-risking.
Positive Factors
Chromatin-focused oncology pipeline
Foghorn’s deliberate focus on chromatin regulators and synthetic-lethal approaches creates a differentiated, hard-to-replicate scientific niche. A multi-program portfolio (SMARCA2, CBP, EP300, ARID1B) increases the chance one asset advances to clinic and supports durable competitive positioning in precision oncology.
Negative Factors
Negative stockholders' equity
Sustained cumulative losses that produced negative equity signal material balance sheet stress and limit financial flexibility. Negative equity can raise cost of capital, complicate covenant negotiations and increases reliance on external financing, a persistent constraint on strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Chromatin-focused oncology pipeline
Foghorn’s deliberate focus on chromatin regulators and synthetic-lethal approaches creates a differentiated, hard-to-replicate scientific niche. A multi-program portfolio (SMARCA2, CBP, EP300, ARID1B) increases the chance one asset advances to clinic and supports durable competitive positioning in precision oncology.
Read all positive factors
Foghorn Therapeutics (FHTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$304.73M
Dividend YieldN/A
Average Volume (3M)157.41K
Price to Earnings (P/E)―
Beta (1Y)1.87
Revenue Growth20.08%
EPS Growth14.06%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.17
Shares Outstanding58,713,920
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.75Price Target Upside122.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.07
Revenue Forecast (FY)$26.76M
Foghorn Therapeutics Business Overview & Revenue Model
Company Description
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company empl...
How the Company Makes Money
As a clinical-stage biotechnology company, Foghorn Therapeutics primarily funds operations through (1) external financing (e.g., equity offerings) and (2) collaboration-related revenue when applicable (such as payments from strategic partnerships)...
Foghorn Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.22M | 30.91M | 22.60M | 34.16M | 19.23M | 1.32M |
| Gross Profit | 6.28M | 27.58M | 22.60M | 34.16M | 19.23M | 1.32M |
| EBITDA | -72.53M | -70.95M | -97.17M | -90.75M | -105.56M | -96.19M |
| Net Income | -75.32M | -74.28M | -86.62M | -98.43M | -108.88M | -101.32M |
Balance Sheet | ||||||
| Total Assets | 222.17M | 198.10M | 283.98M | 285.92M | 404.88M | 519.77M |
| Cash, Cash Equivalents and Short-Term Investments | 184.88M | 158.89M | 243.75M | 234.06M | 345.80M | 154.29M |
| Total Debt | 41.99M | 41.27M | 37.13M | 45.07M | 51.51M | 58.33M |
| Total Liabilities | 298.57M | 306.60M | 329.51M | 363.11M | 404.77M | 422.90M |
| Stockholders Equity | -76.41M | -108.50M | -45.53M | -77.19M | 112.00K | 96.87M |
Cash Flow | ||||||
| Free Cash Flow | -87.42M | -86.15M | -101.31M | -119.33M | 192.40M | -53.56M |
| Operating Cash Flow | -87.40M | -86.10M | -100.41M | -118.11M | 193.61M | -50.25M |
| Investing Cash Flow | 64.92M | 112.04M | -29.90M | 144.45M | -244.32M | 36.17M |
| Financing Cash Flow | 50.66M | 1.02M | 105.43M | 1.78M | 1.76M | 22.42M |
Foghorn Therapeutics Technical Analysis
Positive
5.29
Price Trends
4.47
Positive
4.76
Positive
4.86
Positive
Market Momentum
0.25
Positive
53.64
Neutral
19.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FHTX, the sentiment is Positive. The current price of 5.29 is above the 20-day moving average (MA) of 5.13, above the 50-day MA of 4.47, and above the 200-day MA of 4.86, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 53.64 is Neutral, neither overbought nor oversold. The STOCH value of 19.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FHTX.
Foghorn Therapeutics Risk Analysis
Foghorn Therapeutics disclosed 54 risk factors in its most recent earnings report. Foghorn Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Foghorn Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.98B | -12.62 | -40.99% | ― | -73.07% | -2335.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.23B | -10.02 | -563.89% | ― | 550.00% | -107.04% | |
48 Neutral | $304.73M | -4.44 | 85.78% | ― | 20.08% | 14.06% | |
46 Neutral | $175.03M | -0.75 | -67.65% | ― | 74.84% | 99.51% |
* Healthcare Sector Average
FHTX
Foghorn Therapeutics
5.16
-1.18
-18.61%
TNXP
Tonix Pharma
11.56
-33.19
-74.17%
GLUE
Monte Rosa Therapeutics
23.63
17.97
317.49%
INBX
Inhibrx Biosciences Inc
87.61
64.75
283.25%
Foghorn Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Foghorn Therapeutics Stockholders Approve Directors and Governance Matters
Positive
Jun 24, 2026
At its June 24, 2026 annual meeting, Foghorn Therapeutics stockholders re-elected Douglas Cole, Balkrishan (Simba) Gill and B. Lynne Parshall as Class III directors to serve until the 2029 meeting, reinforcing continuity in the company’s boa...
Business Operations and StrategyFinancial Disclosures
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline
Positive
May 7, 2026
On May 7, 2026, Foghorn Therapeutics reported first quarter 2026 results and a corporate update, highlighting continued progress of its lead SMARCA2 inhibitor FHD-909, being developed with Eli Lilly, in a Phase 1 dose-escalation trial for SMARCA4-...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
Positive
Apr 21, 2026
On April 21, 2026, Foghorn Therapeutics announced preclinical data for several oncology programs presented at the 2026 American Association for Cancer Research Annual Meeting, including its selective SMARCA2 inhibitor FHD-909 and selective CBP, EP...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.